{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:49:15Z","timestamp":1775065755614,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian NHMRC","award":["APP1008473"],"award-info":[{"award-number":["APP1008473"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.pbb.2014.06.004","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T11:07:28Z","timestamp":1402657648000},"page":"167-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0467-4646","authenticated-orcid":false,"given":"Michael","family":"De Santis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamei","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14728214.13.3.479","article-title":"Emerging drugs for schizophrenia","volume":"13","author":"Agid","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0275","first-page":"121","article-title":"An animal model of antipsychotic-induced weight gain","volume":"152","author":"Arjona","year":"2004","journal-title":"Behav Brain Res"},{"issue":"1, Supplement","key":"10.1016\/j.pbb.2014.06.004_bb0360","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0920-9964(03)80835-6","article-title":"DU127090: a novel partial dopamine agonist with antipsychotic activity a putative potent full spectrum antipsychotic with low EPS potential","volume":"60","author":"Arnt","year":"2003","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.004_bb0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00210-006-0092-z","article-title":"In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles","volume":"373","author":"Assi\u00e9","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"S1","key":"10.1016\/j.pbb.2014.06.004_bb0200","first-page":"S251","article-title":"A randomized, double-blind, placebo-controlled study of Bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia","volume":"31","author":"Barbato","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine d-2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics","volume":"18","author":"Bardin","year":"2007","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.pbb.2014.06.004_bb0320","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0149-7634(02)00014-3","article-title":"Multiple neural systems controlling food intake and body weight","volume":"26","author":"Berthoud","year":"2002","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pbb.2014.06.004_bb0100","first-page":"3","article-title":"Aripiprazole versus typical antipsychotic drugs for schizophrenia","author":"Bhattacharjee","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1016\/j.pbb.2014.06.004_bb0170","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2165\/0003495-200868160-00002","article-title":"Upcoming agents for the treatment of schizophrenia","volume":"68","author":"Bishara","year":"2008","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0340","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-007-0698-y","article-title":"In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain","volume":"191","author":"Bortolozzi","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0175","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","article-title":"Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology (Berl Ger)"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0010","first-page":"51","article-title":"Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects","volume":"42","author":"Conley","year":"2005","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"Supplement 2","key":"10.1016\/j.pbb.2014.06.004_bb0070","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0020","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"8","author":"Creese","year":"1996","journal-title":"J Neuropsychiatr"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0269881108089586","article-title":"Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour","volume":"23","author":"Dahan","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.004_bb0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"10.1016\/j.pbb.2014.06.004_bb0280","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.pnpbp.2007.02.009","article-title":"Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats","volume":"31","author":"Deng","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2014.06.004_bb0195","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/JCP.0b013e3181e74555","article-title":"What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?","volume":"30","author":"Deng","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.004_bb0245","article-title":"Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1016\/j.pbb.2014.06.004_bb0255","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0355","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1369-1600.2011.00319.x","article-title":"Bifeprunox: a partial agonist at dopamine D2 and serotonin1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats","volume":"17","author":"Di Clemente","year":"2012","journal-title":"Addict Biol"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0240","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbr.2007.11.017","article-title":"Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats","volume":"188","author":"du Bois","year":"2008","journal-title":"Behav Brain Res"},{"issue":"8","key":"10.1016\/j.pbb.2014.06.004_bb0215","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1517\/13543780903066756","article-title":"Drugs in development for the treatment of schizophrenia","volume":"18","author":"Emsley","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neulet.2009.05.035","article-title":"Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation","volume":"460","author":"Etievant","year":"2009","journal-title":"Neurosci Lett"},{"issue":"17","key":"10.1016\/j.pbb.2014.06.004_bb0060","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/S0960-894X(01)00425-5","article-title":"New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities","volume":"11","author":"Feenstra","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pbb.2014.06.004_bb0305","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1152\/ajpregu.00450.2007","article-title":"Mesolimbic dopamine in obesity and diabetes","volume":"293","author":"Gainetdinov","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"10.1016\/j.pbb.2014.06.004_bb0310","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.neuroscience.2009.02.007","article-title":"Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity","volume":"159","author":"Geiger","year":"2009","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00213-006-0654-2","article-title":"Unique pharmacological profile of aripiprazole as the phasic component buster","volume":"191","author":"Hamamura","year":"2007","journal-title":"Psychopharmacology (Berl Ger)"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.004_bb0260","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2014.06.004_bb0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1017\/S1461145709009948","article-title":"Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects","volume":"12","author":"Han","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.pbb.2014.06.004_bb0150","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.neuroscience.2009.09.041","article-title":"The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain","volume":"164","author":"Han","year":"2009","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.004_bb0285","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain","volume":"27","author":"He","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2014.06.004_bb0185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":"Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients","volume":"29","author":"Henderson","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"Supplement 3(0)","key":"10.1016\/j.pbb.2014.06.004_bb0365","first-page":"S488","article-title":"Bifeprunox: a novel atypical antipsychotic with in vivo 5-HT1A receptor agonistic activity","volume":"15","author":"Herremans","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20132","key":"10.1016\/j.pbb.2014.06.004_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.molbrainres.2004.05.008","article-title":"Differential expression of 5-HT2A and 5-HT2C receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity","volume":"127","author":"Huang","year":"2004","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.pbb.2014.06.004_bb0290","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbr.2006.03.040","article-title":"Olanzapine differently affects 5-HT2a and 2c receptor mRNA expression in the rat brain","volume":"171","author":"Huang","year":"2006","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0220","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.pbb.2014.06.004_bb0345","doi-asserted-by":"crossref","first-page":"251 +","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.pbb.2014.06.004_bb0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.004_bb0085","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.pbb.2014.06.004_bb0110","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","article-title":"Clozapine-induced weight gain predicts improvement in psychopathology","volume":"59","author":"Meltzer","year":"2003","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2014.06.004_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2006.04.048","article-title":"Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat","volume":"540","author":"Naiker","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2014.06.004_bb0230","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"09","key":"10.1016\/j.pbb.2014.06.004_bb0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1017\/S1461145710001343","article-title":"Partial agonists in schizophrenia\u2014why some work and others do not: insights from preclinical animal models","volume":"14","author":"Natesan","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"issue":"03","key":"10.1016\/j.pbb.2014.06.004_bb0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.pbb.2014.06.004_bb0155","first-page":"539","article-title":"Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation anti psychotics","volume":"8","author":"Newman-Tancredi","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pbb.2014.06.004_bb0250","series-title":"A colour atlas of the rat: dissection guide","author":"Olds","year":"1979"},{"key":"10.1016\/j.pbb.2014.06.004_bb0265","first-page":"16","article-title":"Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies","author":"Panariello","year":"2011","journal-title":"Schizophr Res Treat"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2014.06.004_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment \u2014 pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pbb.2014.06.004_bb0065","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008877-200006000-00008","article-title":"Pharmacological and molecular targets in the search for novel antipsychotics","volume":"11","author":"Scatton","year":"2000","journal-title":"Behav Pharmacol"},{"issue":"5562","key":"10.1016\/j.pbb.2014.06.004_bb0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pbb.2014.06.004_bb0125","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"Supplement 1","key":"10.1016\/j.pbb.2014.06.004_bb0095","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","article-title":"Aripiprazole in schizophrenia and schizoaffective disorder: a review","volume":"32","author":"Stip","year":"2010","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.004_bb0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.06.004_bb0035","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.v69n0909","article-title":"Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study","volume":"69","author":"Ujike","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.npp.1301071","article-title":"Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways","volume":"32","author":"Urban","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.004_bb0325","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nn1452","article-title":"How can drug addiction help us understand obesity?","volume":"8","author":"Volkow","year":"2005","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.004_bb0330","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/syn.10075","article-title":"\u201cNonhedonic\u201d food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect","volume":"44","author":"Volkow","year":"2002","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.004_bb0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tics.2010.11.001","article-title":"Reward, dopamine and the control of food intake: implications for obesity","volume":"15","author":"Volkow","year":"2011","journal-title":"Trends Cogn Sci"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/14796708.2.2.153","article-title":"Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors","volume":"2","author":"Wadenberg","year":"2007","journal-title":"Future Neurol"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.004_bb0300","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/14728222.6.5.601","article-title":"The role of dopamine in motivation for food in humans: implications for obesity","volume":"6","author":"Wang","year":"2002","journal-title":"Expert Opin Ther Targets"},{"issue":"06","key":"10.1016\/j.pbb.2014.06.004_bb0040","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1017\/S1461145708008560","article-title":"The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain","volume":"11","author":"Weston-Green","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav Brain Res"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.004_bb0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/13543784.16.6.771","article-title":"Aripiprazole acts as a selective dopamine D2 receptor partial agonist","volume":"16","author":"Wood","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.004_bb0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]Raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.004_bb0050","first-page":"537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br J Pharmacol"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T07:55:42Z","timestamp":1538553342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305714001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":73,"alternative-id":["S0091305714001749"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2014.06.004","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2014.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}